Development of P22 Viral Capsid Nanocomposites as Anti-cancer Drug, Bortezomib (BTZ), Delivery Nanoplatforms

Implementation of P22 Viral Capsids as Intravascular MR T1 Contrast Conjugates via Site-selective Attachment of Gd (III)-chelating agents

TRAIL & EGFR Affibody Dual-display on a Protein Cage Nanoparticle Synergistically Suppresses Tumor Growth.

Target-Switchable Gd(III)-DOTA/Protein Cage Nanoparticle Conjugates with Multiple Targeting Affibody Molecules as Target Selective T1 Contrast Agents for High-field MRI.

Cloaking Nanoparticles with Protein Corona Shield for Targeted Drug Delivery.

A Recombinant Secondary Antibody Mimic as a Target-specific Signal Amplifier and an Antibody Immobilizer in Immunoassays.

Development of an Antibody-binding Modular Nanoplatform for Antibody-guided Targeted Cell Imaging and Delivery.

Lumazine Synthase Protein Nanoparticle-Gd(III)-DOTA Conjugate as a T1 contrast agent for high-field MRI.

Kang, Y., Yeo, M., Choi, H., Jun, H., Eom, S., Park, S. G., Yoon, H., Kim, E.,* and Kang, S.* Lactate Oxidase/vSIRPa Conjugates Efficiently Consume Tumor-produced Lactate and Locally Produce Tumor-necrotic H2O2 to Suppress Tumor Growth.

Choi, H., Yeo, M., Kang, Y., Kim, H. J., Park, S. G., Jang, E., Park, S. H.,* Kim, E.,* and Kang, S.* Lactate Oxidase/Catalase-displaying Nanoparticles Efficiently Consume Lactate in the Tumor Microenvironment to Effectively Suppress Tumor Growth.